Last week, VERIGRAFT participated in Swiss Nordic Bio 2025 in Zürich, where our CEO Petter Björquist was interviewed about our groundbreaking technology. Watch the full interview here.
What does VERIGRAFT do?
We are a Swedish biotech company specializing in cardiovascular diseases, and our technology involves providing patients with new blood vessels—but in a way that no one else does today.
Our method is based on “changing the identity of a donated vascular graft so that it matches the patient’s immune system”, he says. This means the graft can be transplanted without causing an immune reaction, which is a significant advantage over existing alternatives.
Is there any competition?
“I would say, in our area, no,” says Petter Björquist. There are other companies that have tried to do this in the past and companies that are working in other areas, but when it comes to vascular disease and cardiovascular disease, there is no direct competition.
What do healthcare professionals say?
With clinical data confirming that our technology works in real patients, the reception from the healthcare community has been very positive. “People are really positive and are really looking forward to seeing this in a broader use,” says Björquist.
Want to learn more? Watch the full interview here and follow us on LinkedIn for more updates.
#Biotech #RegenerativeMedicine #VascularGrafts #Innovation